CLINICAL CONSIDERATIONS
SPECIFIC
Immunotherapy builds a population of immune cells over time that specifically target cancer cells1-4
Learn more by watching Immunotherapy Is Tumor-Specific (2:03)
ADAPTABLE
The activated immune system adapts as cancer mutates, enabling it to recognize new tumor antigens2-3,5-6
Learn more by watching Immunotherapy Is Adaptable (2:42)
DURABLE
The immune system has memory and remains primed to stimulate a tumor-specific response1,7
Learn more by watching Immunotherapy is Durable (2:18)
Patients may respond differently to immunotherapy than to traditional cancer agents.
-
Immunotherapy targets the tumor over time, so although response may occur more slowly than with traditional cytotoxic therapies, the immune effect is potentially adaptable and durable2-4
-
RECIST criteria were designed to assess response to traditional cytotoxic agents so they are not as relevant for immunotherapy, which works differently2-4
Learn more by watching Immunotherapy Works Differently (2:44)
REFERENCES
- Murphy K, Travers P, Walport M, eds. Janeway’s Immunobiology. 7th ed. Garland Science, Taylor & Frances Group, LLC. New York, NY: 2008.
- Sharma P, Wagner K, Wolchok JD, Allison JP. Nat Rev Cancer. 2011;11:805-812.
- Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. CA Cancer J Clin. 2012;62(5):309-335.
- Mellman I, Coukos G, Dranoff G. Nature. 2011;480:480-489.
- Ribas A, Butterfield LH, Glaspy JA, Economou JS. J Clin Oncol. 2003;21:2415-2432.
- Disis ML, Strickler JH, Wallace D, et al. J Clin Oncol. 2008;26(suppl):(May 20 suppl; abstr 3015).
- Klebanoff CA, Gattinoni L, Restifo NP. Immunol Rev. 2006;211:214-224.
